| Drug Name |
Etophos |
| Drug ID |
BADD_D00853 |
| Description |
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. |
| Indications and Usage |
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01CB01 |
| DrugBank ID |
DB00773
|
| KEGG ID |
D04107
|
| MeSH ID |
C061400
|
| PubChem ID |
60668
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
53104-7514; 53183-8538; 68001-265; 0143-9512; 0143-9510; 0143-9511; 63323-104; 0378-3266; 16729-114; 0143-9376; 55361-0006; 57884-0008; 0703-5656; 0703-5653; 0703-5657 |
| Synonyms |
etoposide phosphate | BMY-40481 | BMY 40481-30 | BMY-40481-30 | Etophos | Etopophos | Etopofos |
